Inducteurs du cytochrome P-450 CYP2D6 : Questions médicales fréquentes
Nom anglais: Cytochrome P-450 CYP2D6 Inducers
Descriptor UI:D065699
Tree Number:D27.505.519.349.500
Termes MeSH sélectionnés :
Diagnostic and Statistical Manual of Mental Disorders
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inducteurs du cytochrome P-450 CYP2D6 : Questions médicales les plus fréquentes",
"headline": "Inducteurs du cytochrome P-450 CYP2D6 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inducteurs du cytochrome P-450 CYP2D6 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-30",
"dateModified": "2025-02-24",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inducteurs du cytochrome P-450 CYP2D6"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Inducteurs des enzymes du cytochrome P-450",
"url": "https://questionsmedicales.fr/mesh/D065693",
"about": {
"@type": "MedicalCondition",
"name": "Inducteurs des enzymes du cytochrome P-450",
"code": {
"@type": "MedicalCode",
"code": "D065693",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.349"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inducteurs du cytochrome P-450 CYP2D6",
"alternateName": "Cytochrome P-450 CYP2D6 Inducers",
"code": {
"@type": "MedicalCode",
"code": "D065699",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Andrea Gaedigk",
"url": "https://questionsmedicales.fr/author/Andrea%20Gaedigk",
"affiliation": {
"@type": "Organization",
"name": "Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA."
}
},
{
"@type": "Person",
"name": "J Steven Leeder",
"url": "https://questionsmedicales.fr/author/J%20Steven%20Leeder",
"affiliation": {
"@type": "Organization",
"name": "Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA."
}
},
{
"@type": "Person",
"name": "Vincent S Staggs",
"url": "https://questionsmedicales.fr/author/Vincent%20S%20Staggs",
"affiliation": {
"@type": "Organization",
"name": "School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA."
}
},
{
"@type": "Person",
"name": "Robin E Pearce",
"url": "https://questionsmedicales.fr/author/Robin%20E%20Pearce",
"affiliation": {
"@type": "Organization",
"name": "Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA."
}
},
{
"@type": "Person",
"name": "Yan Pan",
"url": "https://questionsmedicales.fr/author/Yan%20Pan",
"affiliation": {
"@type": "Organization",
"name": "Department of Biomedical Science, University of Nottingham, Malaysia Campus, Semenyih, Selangor, Malaysia."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Clinical high at-risk mental state in young subjects accessing a mental disorder prevention service in Italy.",
"datePublished": "2022-07-03",
"url": "https://questionsmedicales.fr/article/35878479",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.psychres.2022.114710"
}
},
{
"@type": "ScholarlyArticle",
"name": "Lifetime prevalence and treatment of mental disorders in Saudi youth and adolescents.",
"datePublished": "2023-04-15",
"url": "https://questionsmedicales.fr/article/37061556",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-33005-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "The association of stroke with mental and physical disorders in US adults: A nationally representative study.",
"datePublished": "2023-10-18",
"url": "https://questionsmedicales.fr/article/37897836",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jpsychires.2023.10.035"
}
},
{
"@type": "ScholarlyArticle",
"name": "Extra Movements in Healthy People: Challenging the Definition and Diagnostic Practice of Tic Disorders.",
"datePublished": "2023-01-18",
"url": "https://questionsmedicales.fr/article/36565297",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/ana.26586"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prevalence of mental disorders in the elderly population 5 years after the Lushan earthquake in Ya'an, China.",
"datePublished": "2022-08-06",
"url": "https://questionsmedicales.fr/article/35932308",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00127-022-02323-w"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Mécanismes moléculaires de l'action pharmacologique",
"item": "https://questionsmedicales.fr/mesh/D045504"
},
{
"@type": "ListItem",
"position": 5,
"name": "Inducteurs des enzymes du cytochrome P-450",
"item": "https://questionsmedicales.fr/mesh/D065693"
},
{
"@type": "ListItem",
"position": 6,
"name": "Inducteurs du cytochrome P-450 CYP2D6",
"item": "https://questionsmedicales.fr/mesh/D065699"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inducteurs du cytochrome P-450 CYP2D6 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inducteurs du cytochrome P-450 CYP2D6",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inducteurs du cytochrome P-450 CYP2D6",
"description": "Comment identifier un inducteur du CYP2D6 ?\nQuels tests sont utilisés pour évaluer l'activité du CYP2D6 ?\nQuels signes indiquent une induction du CYP2D6 ?\nPeut-on mesurer l'activité du CYP2D6 ?\nQuels médicaments sont des inducteurs connus ?",
"url": "https://questionsmedicales.fr/mesh/D065699?mesh_terms=Diagnostic+and+Statistical+Manual+of+Mental+Disorders&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inducteurs du cytochrome P-450 CYP2D6",
"description": "Quels symptômes peuvent résulter d'une induction du CYP2D6 ?\nComment l'induction affecte-t-elle les médicaments ?\nY a-t-il des effets secondaires liés aux inducteurs ?\nQuels signes cliniques peuvent alerter sur une induction ?\nL'induction peut-elle causer des symptômes d'intoxication ?",
"url": "https://questionsmedicales.fr/mesh/D065699?mesh_terms=Diagnostic+and+Statistical+Manual+of+Mental+Disorders&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inducteurs du cytochrome P-450 CYP2D6",
"description": "Comment prévenir l'induction du CYP2D6 ?\nLes patients doivent-ils être informés des inducteurs ?\nQuelles précautions prendre lors de la prescription ?\nLes médecins doivent-ils surveiller les inducteurs ?\nY a-t-il des recommandations pour les prescripteurs ?",
"url": "https://questionsmedicales.fr/mesh/D065699?mesh_terms=Diagnostic+and+Statistical+Manual+of+Mental+Disorders&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inducteurs du cytochrome P-450 CYP2D6",
"description": "Comment gérer l'induction du CYP2D6 ?\nPeut-on utiliser des inhibiteurs du CYP2D6 ?\nQuels médicaments sont souvent ajustés ?\nY a-t-il des alternatives aux inducteurs ?\nComment surveiller l'efficacité du traitement ?",
"url": "https://questionsmedicales.fr/mesh/D065699?mesh_terms=Diagnostic+and+Statistical+Manual+of+Mental+Disorders&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inducteurs du cytochrome P-450 CYP2D6",
"description": "Quelles complications peuvent survenir avec l'induction ?\nL'induction peut-elle entraîner des hospitalisations ?\nQuels risques sont associés à l'induction ?\nComment gérer les complications liées à l'induction ?\nY a-t-il des complications à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D065699?mesh_terms=Diagnostic+and+Statistical+Manual+of+Mental+Disorders&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inducteurs du cytochrome P-450 CYP2D6",
"description": "Quels sont les facteurs de risque d'induction ?\nL'âge influence-t-il l'induction du CYP2D6 ?\nLes habitudes de vie jouent-elles un rôle ?\nY a-t-il des prédispositions génétiques ?\nLes interactions médicamenteuses sont-elles un facteur ?",
"url": "https://questionsmedicales.fr/mesh/D065699?mesh_terms=Diagnostic+and+Statistical+Manual+of+Mental+Disorders&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un inducteur du CYP2D6 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par l'analyse des médicaments et leur effet sur le métabolisme."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité du CYP2D6 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des dosages de médicaments peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une induction du CYP2D6 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une diminution de l'efficacité des médicaments métabolisés par CYP2D6 peut indiquer une induction."
}
},
{
"@type": "Question",
"name": "Peut-on mesurer l'activité du CYP2D6 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'activité peut être mesurée par des tests de métabolisme de médicaments spécifiques."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont des inducteurs connus ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme la rifampicine et la carbamazépine sont des inducteurs connus."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent résulter d'une induction du CYP2D6 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une induction peut entraîner une réduction de l'efficacité des médicaments, causant des symptômes de maladie."
}
},
{
"@type": "Question",
"name": "Comment l'induction affecte-t-elle les médicaments ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut réduire la concentration plasmatique des médicaments, diminuant leur effet thérapeutique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires liés aux inducteurs ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires peuvent survenir si les médicaments perdent leur efficacité."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques peuvent alerter sur une induction ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes de non-réponse au traitement peuvent alerter sur une induction du CYP2D6."
}
},
{
"@type": "Question",
"name": "L'induction peut-elle causer des symptômes d'intoxication ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Indirectement, si des médicaments sont sous-dosés, cela peut entraîner des symptômes d'intoxication."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'induction du CYP2D6 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les inducteurs connus et surveiller les interactions médicamenteuses."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils être informés des inducteurs ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation des patients sur les inducteurs est cruciale pour éviter des complications."
}
},
{
"@type": "Question",
"name": "Quelles précautions prendre lors de la prescription ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évaluer les antécédents médicamenteux et les interactions potentielles avant de prescrire."
}
},
{
"@type": "Question",
"name": "Les médecins doivent-ils surveiller les inducteurs ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surveillance régulière des médicaments inducteurs est recommandée."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations pour les prescripteurs ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des lignes directrices existent pour éviter les interactions avec les inducteurs."
}
},
{
"@type": "Question",
"name": "Comment gérer l'induction du CYP2D6 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est essentiel d'ajuster les doses des médicaments affectés par l'induction."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser des inhibiteurs du CYP2D6 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des inhibiteurs peuvent être utilisés pour contrer l'effet des inducteurs."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont souvent ajustés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antidépresseurs et les antipsychotiques sont souvent ajustés en cas d'induction."
}
},
{
"@type": "Question",
"name": "Y a-t-il des alternatives aux inducteurs ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des médicaments non inducteurs peuvent être prescrits pour éviter l'interaction."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'efficacité du traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suivis réguliers et des dosages de médicaments sont nécessaires pour évaluer l'efficacité."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'induction ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent une inefficacité thérapeutique et des effets indésirables."
}
},
{
"@type": "Question",
"name": "L'induction peut-elle entraîner des hospitalisations ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des hospitalisations peuvent être nécessaires en cas de complications graves."
}
},
{
"@type": "Question",
"name": "Quels risques sont associés à l'induction ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des interactions médicamenteuses et des effets secondaires graves."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à l'induction ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est crucial d'ajuster les traitements et de surveiller les patients de près."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications à long terme ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications à long terme peuvent inclure des effets résiduels sur le métabolisme."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque d'induction ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'utilisation de certains médicaments et des variations génétiques."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il l'induction du CYP2D6 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge peut affecter le métabolisme et la réponse aux inducteurs."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie jouent-elles un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes comme l'alcool et le tabac peuvent influencer l'induction."
}
},
{
"@type": "Question",
"name": "Y a-t-il des prédispositions génétiques ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines variations génétiques peuvent augmenter le risque d'induction."
}
},
{
"@type": "Question",
"name": "Les interactions médicamenteuses sont-elles un facteur ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les interactions avec d'autres médicaments peuvent augmenter le risque d'induction."
}
}
]
}
]
}
We aim to assess how functioning, depressive symptoms, and psychotic symptoms are associated with different numbers of Clinical High At-Risk Mental State (CHARMS) categories. In this cross-sectional s...
Previous global and regional studies indicate that adolescents and young adults (i.e., youth) are affected by various mental disorders with lifelong consequences. However, there are no national estima...
Stroke has been linked to various physical and mental disorders, with both stroke and its comorbidities significantly impacting public health. In this population-based study, we evaluate the relations...
The occurrence of motor/vocal tics, that is, "extra movements" and/or "extra vocalizations," is the leading diagnostic criterion for tic disorders. We show that extra movements are common also in heal...
This study aimed to explore the prevalence and distribution of mental disorders in the elderly population 5 years after the Lushan earthquake in Ya'an, China....
A multi-stage, group-matching random sampling method was adopted with 2579 elderly participants (≥ 60 years old) who were interviewed from January to May 2019. Preliminary screening was conducted usin...
A total of 2561 participants were included in this study with complete data. The weighted lifetime prevalence of all mental disorders in the elderly was 16.2% (95% CI 15.3-17.1), and the weighted 12-m...
The results of this study show that mental health status of the elderly in Ya'an area differ by socio-economic development, geographical location, and natural disasters. The social and economic develo...
Schizoaffective disorder (SAD) remains a controversial diagnosis in terms of necessity and reliability....
We assessed diagnostic patterns of SAD and schizophrenia (SZ) among hospitalized psychiatric patients over a fifty-year period....
Data from the Israeli National Psychiatric Registry on 16,341 adults diagnosed with SZ or SAD, hospitalized at least twice in 1963-2017, were analyzed. Stability between most-frequent, first and last ...
Reliability between last and first diagnosis was 60 % for SAD and 94 % for SZ. Agreement between first and most-frequent diagnosis was 86 % for SAD and 92 % for SZ. Diagnostic shifts differ between pe...
A SAD diagnosis is less stable than SZ. The incidence of a SAD diagnosis increased after DSM-5, despite stricter diagnostic criteria. The SZ-SAD group exhibited the poorest outcomes. SAD may evolve ov...
Here we report the reliability and test/re-test validity of a Castillan version of the PCL-5 (PCL5-C) in mental health nurses....
A sample of 52 consecutive nurses was recruited from two psychiatric hospitals and four psychiatrists units of general hospitals in Madrid, Spain....
We detected high internal consistency for the study questionnaire at the test assessment (n = 52) and at retest 0.929 and 0.935, respectively, by total Cronbach's α. All of the items at test and re-te...
Reproducibility analysis showed excellent test/re-test reliability for the total score and each item. Based on our findings, we conclude that the PCL5-C is a valid and reliable questionnaire when appl...
The confluence of conflict-, climate-, and public health-related emergencies in Mozambique increases the risk of posttraumatic stress disorder (PTSD). Few brief screening tools for PTSD have been vali...
This study recruited 957 participants who completed the Mini-International Neuropsychiatric Interview-Plus (MINI-Plus) and PC-PTSD-5, a convenience sample from primary and tertiary care settings in Ma...
Internal consistency of the PC-PTSD-5 was high (KR-20 = 0.837), and confirmatory factor analysis suggested that a single PTSD factor fits the data well. PC-PTSD-5 items were moderately correlated with...
Screening with the PC-PTSD-5 may facilitate case detection and linkages to appropriate treatment for individuals affected by potentially traumatic events in Mozambique. (PsycInfo Database Record (c) 2...
This paper presents results of a study on the Polish adaptation of the Personality Inventory for ICD-11 (PiCD), which was developed to measure pathological traits under a new, dimensional model of per...
The study involved a non-clinical sample of N = 597 adults (51.4% female; Mage = 30.24 years; SD = 12.07 years). For convergent and divergent validity, Personality Inventory for DSM-5 (PID-5) and Big ...
The results showed the Polish adaptation of the PiCD to be reliable and valid. Cronbach's alpha coefficient for PiCD scale scores ranged from 0.77 to 0.87 (Mα = 0.82). The four-factor structure of PiC...
Obtained data demonstrate satisfactory internal consistency, factorial validity, and convergent-discriminant validity of the Polish adaptation of PiCD in a non-clinical sample....
Impulse control disorders (ICDs) are iatrogenic and idiopathic conditions with psychosocial and economic consequences for the affected individuals and their families (e.g. bankruptcy and divorce). How...
To contextualize the ICD diagnostic construct, we provided an overview of its origins in past centuries and followed its development across multiple editions of the Diagnostic and Statistical Manual a...
Two independent roots of the ICD construct emerged: (a) the interest in behavioral excess as expressed in encyclopedic compilations (18th century) and (b) the juridical debate on disruptive conduct an...
The reasons that made impulse control disorders (ICDs) difficult to define from their first conceptualization are the same reasons that now complicate taxonomic efforts and diagnosis. Tracing back ICD...